GRI Bio Inc. (GRI)
GRI Bio Statistics
Share Statistics
GRI Bio has 525.36K shares outstanding. The number of shares has increased by -1.53% in one year.
| Shares Outstanding | 525.36K |
| Shares Change (YoY) | -1.53% |
| Shares Change (QoQ) | -0.32% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 525.11K |
| Failed to Deliver (FTD) Shares | 90 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 924.63K, so 10.35% of the outstanding shares have been sold short.
| Short Interest | 924.63K |
| Short % of Shares Out | 10.35% |
| Short % of Float | 10.36% |
| Short Ratio (days to cover) | 0.1 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.68. GRI Bio's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -0.68 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for GRI Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.43 |
| Quick Ratio | 3.43 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $7.26M |
| Profits Per Employee | $-4.35M |
| Employee Count | 3 |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2.77M |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -98.67% in the last 52 weeks. The beta is -1.72, so GRI Bio's price volatility has been lower than the market average.
| Beta | -1.72 |
| 52-Week Price Change | -98.67% |
| 50-Day Moving Average | 7.32 |
| 200-Day Moving Average | 12.9 |
| Relative Strength Index (RSI) | 21.55 |
| Average Volume (20 Days) | 268.99K |
Income Statement
In the last 12 months, GRI Bio had revenue of 21.77M and earned -13.04M in profits. Earnings per share was -28.25.
| Revenue | 21.77M |
| Gross Profit | 21.71M |
| Operating Income | -11.39M |
| Net Income | -13.04M |
| EBITDA | -10.9M |
| EBIT | -10.96M |
| Earnings Per Share (EPS) | -28.25 |
Balance Sheet
The company has 5.03M in cash and 119K in debt, giving a net cash position of 4.91M.
| Cash & Cash Equivalents | 5.03M |
| Total Debt | 119K |
| Net Cash | 4.91M |
| Retained Earnings | -39.74M |
| Total Assets | 5.74M |
| Working Capital | 911K |
Cash Flow
In the last 12 months, operating cash flow was -8.61M and capital expenditures 0, giving a free cash flow of -8.61M.
| Operating Cash Flow | -8.61M |
| Capital Expenditures | 0 |
| Free Cash Flow | -8.61M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -52.31% |
| FCF Margin | -39.56% |
Dividends & Yields
GRI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for GRI is $195.5, which is 12677.8% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $195.5 |
| Price Target Difference | 12677.8% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Feb 24, 2025. It was a backward split with a ratio of 1:17.
| Last Split Date | Feb 24, 2025 |
| Split Type | backward |
| Split Ratio | 1:17 |
Scores
| Altman Z-Score | 10.85 |
| Piotroski F-Score | 1 |